• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

接受替沙格韦单抗-西加韦单抗预防的免疫功能低下患者中早发性严重急性呼吸综合征冠状病毒2感染的特征

Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis.

作者信息

Ordaya Eloy E, Beam Elena, Yao Joseph D, Razonable Raymund R, Vergidis Paschalis

机构信息

Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

出版信息

Open Forum Infect Dis. 2022 Jun 7;9(7):ofac283. doi: 10.1093/ofid/ofac283. eCollection 2022 Jul.

DOI:10.1093/ofid/ofac283
PMID:35859990
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9214166/
Abstract

Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving tixagevimab-cilgavimab. This study emphasizes the need to maintain additional measures to prevent COVID-19 during periods of high severe acute respiratory syndrome coronavirus 2 transmission.

摘要

替沙格韦单抗-西加韦单抗被批准用于免疫功能低下宿主的2019冠状病毒病（COVID-19）暴露前预防。在此，我们报告了8例在接受替沙格韦单抗-西加韦单抗后不久感染COVID-19患者的临床特征。本研究强调在严重急性呼吸综合征冠状病毒2传播率高的时期，需要维持额外措施来预防COVID-19。

相似文献

1
Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis.接受替沙格韦单抗-西加韦单抗预防的免疫功能低下患者中早发性严重急性呼吸综合征冠状病毒2感染的特征
Open Forum Infect Dis. 2022 Jun 7;9(7):ofac283. doi: 10.1093/ofid/ofac283. eCollection 2022 Jul.
2
Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients.替沙格韦单抗和西加韦单抗（Evusheld）用于 1112 例严重免疫功能低下患者的 COVID-19 暴露前预防。
Clin Microbiol Infect. 2022 Dec;28(12):1654.e1-1654.e4. doi: 10.1016/j.cmi.2022.07.015. Epub 2022 Aug 1.
3
Clinical characteristics and COVID-19-related outcomes of immunocompromised patients receiving tixagevimab/cilgavimab pre-exposure prophylaxis in Japan.日本接受替沙格韦单抗/西加韦单抗暴露前预防的免疫功能低下患者的临床特征及与COVID-19相关的结局
J Infect Chemother. 2025 Jan;31(1):102467. doi: 10.1016/j.jiac.2024.07.007. Epub 2024 Jul 8.
4
Safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in kidney transplant recipients: a multicenter retrospective cohort study.替沙格韦单抗/西加韦单抗用于肾移植受者暴露前预防的安全性和有效性：一项多中心回顾性队列研究。
J Nephrol. 2024 Jul;37(6):1539-1550. doi: 10.1007/s40620-024-01889-9. Epub 2024 May 23.
5
Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review.替沙格韦单抗/西加韦单抗用于 COVID-19 的预防和治疗：综述。
Expert Rev Anti Infect Ther. 2022 Dec;20(12):1517-1527. doi: 10.1080/14787210.2022.2134118. Epub 2022 Oct 27.
6
SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients-A Single-Center Experience.Sotrovimab 和 Tixagevimab/Cilgavimab 用于免疫功能低下患者的 SARS-CoV-2 暴露前预防：单中心经验。
Viruses. 2022 Oct 17;14(10):2278. doi: 10.3390/v14102278.
7
Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients.系统评价和荟萃分析：替沙格韦单抗/西加韦单抗用于预防免疫功能低下患者 COVID-19 的临床效果。
Br J Haematol. 2023 Jun;201(5):813-823. doi: 10.1111/bjh.18782. Epub 2023 Apr 3.
8
Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.在TACKLE随机试验中，使用AZD7442（替沙格韦单抗/西加韦单抗）进行门诊治疗可预防6个月内的COVID-19住院，并减少症状进展。
Infect Dis Ther. 2023 Sep;12(9):2269-2287. doi: 10.1007/s40121-023-00861-7. Epub 2023 Sep 26.
9
Safety and Efficacy of Intramuscular Tixagevimab-Cilgavimab in Prevention of COVID-19 in Patients Who Are Immunocompromised.替沙格韦单抗-西加韦单抗肌内注射剂用于预防免疫功能低下的 COVID-19 患者的安全性和有效性。
Perm J. 2023 Dec 15;27(4):44-54. doi: 10.7812/TPP/22.180. Epub 2023 Sep 18.
10
Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis.SARS-CoV-2 奥密克戎亚变种在 COVID-19 免疫功能低下患者中的基因和表型分析，这些患者在接受 tixagevimab-cilgavimab 预防治疗后。
J Clin Virol. 2023 Mar;160:105382. doi: 10.1016/j.jcv.2023.105382. Epub 2023 Jan 26.

引用本文的文献

1
Unveiling protection: a meta-analysis of tixagevimab-cilgavimab prophylaxis in 28,950 transplant recipients and immunocompromised patients against COVID-19.揭示保护作用：对28950名移植受者和免疫功能低下患者使用替沙格韦单抗-西加韦单抗预防COVID-19的荟萃分析
Virol J. 2025 Jun 2;22(1):178. doi: 10.1186/s12985-025-02814-7.
2
Pre-Exposure Prophylaxis and Treatment with Tixagevimab/Cilgavimab for COVID-19 among Immunocompromised Pediatric Patients.替沙格韦单抗/西加韦单抗用于免疫功能低下儿科患者的COVID-19暴露前预防和治疗
J Clin Med. 2024 Mar 31;13(7):2029. doi: 10.3390/jcm13072029.
3
The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis.替沙格韦单抗/西加韦单抗（Evusheld）在免疫功能低下患者 COVID-19 预防和治疗中的疗效：系统评价和荟萃分析。
Eur J Med Res. 2024 Jan 5;29(1):27. doi: 10.1186/s40001-023-01549-x.
4
Efficacy and Safety of Anti-SARS-CoV-2 Antiviral Agents and Monoclonal Antibodies in Patients with SLE: A Case-Control Study.SLE 患者抗 SARS-CoV-2 抗病毒药物和单克隆抗体的疗效和安全性：一项病例对照研究。
Biomolecules. 2023 Aug 22;13(9):1273. doi: 10.3390/biom13091273.
5
Pre-exposure Prophylaxis with Tixagevimab-cilgavimab did not Reduce Severity of COVID-19 in Lung Transplant Recipients with Breakthrough Infection.替沙格韦单抗-西加韦单抗暴露前预防未能降低发生突破性感染的肺移植受者的COVID-19严重程度。
Transplant Direct. 2023 May 12;9(6):e1485. doi: 10.1097/TXD.0000000000001485. eCollection 2023 Jun.
6
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi.替沙格韦单抗/西加韦单抗对接受布鲁顿酪氨酸激酶抑制剂治疗的淋巴增殖性疾病患者的暴露前预防
Hemasphere. 2023 May 4;7(5):e880. doi: 10.1097/HS9.0000000000000880. eCollection 2023 May.
7
Antiviral Treatment of Coronavirus Disease-2019 Pneumonia.新型冠状病毒肺炎抗病毒治疗。
Clin Chest Med. 2023 Jun;44(2):279-297. doi: 10.1016/j.ccm.2022.11.008. Epub 2022 Nov 28.
8
Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience.替沙格韦单抗/西加韦单抗在 SARS-CoV-2 预防和治疗中的作用：临床经验的综合评价。
Viruses. 2022 Dec 30;15(1):118. doi: 10.3390/v15010118.
9
Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis.替沙格韦单抗/西加韦单抗预防新型冠状病毒肺炎（暴露前预防）的疗效和安全性：一项系统评价和荟萃分析
Diseases. 2022 Dec 1;10(4):118. doi: 10.3390/diseases10040118.
10
The Prevention of COVID-19 in High-Risk Patients Using Tixagevimab-Cilgavimab (Evusheld): Real-World Experience at a Large Academic Center.高风险患者使用替沙格韦单抗-西加韦单抗（Evusheld）预防 COVID-19：大型学术中心的真实世界经验。
Am J Med. 2023 Jan;136(1):96-99. doi: 10.1016/j.amjmed.2022.08.019. Epub 2022 Sep 29.

本文引用的文献

1
SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.SARS-CoV-2 奥密克戎 BA.5：与关注的病毒变体相比，其对潜在体液反应的趋化性和逃逸能力以及对临床免疫疗法的耐药性不断进化。
EBioMedicine. 2022 Oct;84:104270. doi: 10.1016/j.ebiom.2022.104270. Epub 2022 Sep 18.
2
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.肌肉注射 AZD7442（替沙格韦单抗-西加韦单抗）预防新冠病毒感染。
N Engl J Med. 2022 Jun 9;386(23):2188-2200. doi: 10.1056/NEJMoa2116620. Epub 2022 Apr 20.
3
Early Genomic, Epidemiological, and Clinical Description of the SARS-CoV-2 Omicron Variant in Mexico City.墨西哥城新冠病毒奥密克戎变种的早期基因组、流行病学和临床描述
Viruses. 2022 Mar 6;14(3):545. doi: 10.3390/v14030545.
4
Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons.冠状病毒耐药性数据库 (CoV-RDB)：SARS-CoV-2 对单克隆抗体、恢复期血浆和接种者血浆的敏感性。
PLoS One. 2022 Mar 9;17(3):e0261045. doi: 10.1371/journal.pone.0261045. eCollection 2022.
5
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans.SARS-CoV-2 单克隆抗体组合药物 AZD7442 在非人类灵长类动物中具有保护作用，在人体内半衰期延长。
Sci Transl Med. 2022 Mar 9;14(635):eabl8124. doi: 10.1126/scitranslmed.abl8124.
6
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.mRNA COVID-19 疫苗 3 剂接种与 SARS-CoV-2 奥密克戎和德尔塔变异株引起的有症状感染之间的关联。
JAMA. 2022 Feb 15;327(7):639-651. doi: 10.1001/jama.2022.0470.
7
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies.一种传染性 SARS-CoV-2 B.1.1.529 奥密克戎病毒能够逃避治疗性单克隆抗体的中和作用。
Nat Med. 2022 Mar;28(3):490-495. doi: 10.1038/s41591-021-01678-y. Epub 2022 Jan 19.
8
Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies.同源或异源加强针可降低奥密克戎变异株对灭活疫苗中和抗体的逃逸。
Emerg Microbes Infect. 2022 Dec;11(1):477-481. doi: 10.1080/22221751.2022.2030200.
9
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.奥密克戎对抗体中和作用的逃逸显著。
Nature. 2022 Feb;602(7898):671-675. doi: 10.1038/s41586-021-04389-z. Epub 2021 Dec 23.
10
Breakthrough COVID-19 after SARS-CoV-2 vaccination in solid organ transplant recipients: An analysis of symptomatic cases and monoclonal antibody therapy.SARS-CoV-2 疫苗接种后突破 COVID-19 在实体器官移植受者中的发生：症状病例分析和单克隆抗体治疗。
Transpl Infect Dis. 2022 Apr;24(2):e13779. doi: 10.1111/tid.13779. Epub 2022 Jan 31.